IP Library › Granted Patent US 8,227,436
Granted Patent B2
US 8,227,436 · App. 11/900,412 · Granted Jul 24, 2012

Method of inducing an immune response

Assignee: University of Queensland
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,436
App. No.
11/900,412
Granted
Jul 24, 2012
Kind
B2
Abstract

A method is provided for inducing or enhancing an immune response in a mammal to a target polypeptide expressed in a plurality of cells of the mammal, which method comprises administering to the mammal an inhibitory nucleic acid which targets a region of a ribonucleic acid (RNA) which encodes said polypeptide. Also provided is a pharmaceutical composition comprising an inhibitory nucleic acid which targets a region of an RNA which encodes a target polypeptide expressed in a plurality of cells of a mammal, such that translation of an aberrant form of the target polypeptide occurs in said cells, said truncated form of the target polypeptide comprising one or more T cell epitopes; together with a pharmaceutically acceptable carrier or diluent.

Claims (7)

1. A method of inducing or enhancing an immune response in a mammal to an E6/E7 polypeptide of HPV expressed in a plurality of cells of the mammal, which method comprises administering to the mammal an shRNA which targets the E6/E7 region of a human papillomavirus (HPV) mRNA ribonucleic acid (RNA) which encodes an E6/E7 target polypeptide, said region comprising nucleotides 181-198 of SEQ ID NO:3.

2. A method according to claim 1 wherein at least a portion of the polypeptide, which portion comprises a T cell epitope, is presented on the surface of the cells bound to major histocompatibility complex (MHC).

3. A method according to claim 1 wherein the dose of inhibitory nucleic acid is insufficient to kill directly the cells expressing that target polypeptide.

4. The method of claim 1 , wherein the shRNA comprises a sense sequence comprising nucleotides 3-20 of SEQ ID NO:9, and an antisense sequence comprising nucleotides 30-47 of SEQ ID NO:9.

5. The method of claim 1 , wherein the shRNA comprises a sense sequence consisting of nucleotides 3-20 of SEQ ID NO:9, and an antisense sequence consisting of nucleotides 30-47 of SEQ ID NO:9.

6. The method of claim 4 , wherein the shRNA comprises SEQ ID NO:9.

7. The method of claim 4 , wherein the shRNA consists of SEQ ID NO:9.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2008
From: MCMILLAN, NIGEL; LEGGATT, GRAHAM; GU, WENYI
To: QUEENSLAND, UNIVERSITY OF, THE
Reel/Frame 021575/0395 →
Continuity (2)
Provisional Application 60880547 · Jan 16, 2007
Related Publication 20080214485A1 · Sep 4, 2008